Advanced Navigation completes Series B funding round – Advanced Navigation, a developer of AI robotics and navigation technology, has raised $68 million in a Series B funding round. The Series B round was led by global investment firm KKR.
The funding round includes participation from new investors such as deep learning venture firm AI Capital and existing investors, including Main Sequence, the Hon. Malcolm Turnbull AC, In-Q-Tel, and Our Innovation Fund, bringing Advanced Navigation’s total amount raised to more than $85 million.
Morse Micro Supercharges its Series B Funding Round with AU $30 Million Top-up from Major Superannuation Funds and Others – Morse Micro, a fabless semiconductor company reinventing Wi-Fi for the Internet of Things (IoT), today announced an AU $30 million top-up of its Series B funding. TelstraSuper, HESTA, Hostplus and NGS (managed by Blackbird Ventures) and UniSuper (managed by Uniseed) participated in the round.
Need to write a business plan? There is no better tool than our business plan template.
FogPharma’s $178M Funding Leads Way as 7 Biotechs Raise Cash for Cancer Drugs – Cancer continues to be a big draw for biotech investors, and cancer research is well represented in the past week’s financing activity. Seven biotech companies announced financing rounds to support a range of tumor-targeting therapeutic approaches that include small molecules, oncolytic viruses, and peptide drugs.
Peptides are the focus of FogPharma, which raised the largest financing round of the Thanksgiving holiday-shortened week. The Cambridge, Massachusetts-based biotech is developing a new class of peptide drugs that address therapeutic targets deemed “undruggable.” FogPharma is led by CEO Greg Verdine, a former Harvard professor who has become a biotech entrepreneur. Verdine is also chief executive of LifeMine Therapeutics, a GSK-partnered startup that analyzes fungal genes to discover new drugs.
Bionaut Labs Closes $43M in Series B Led by Khosla Ventures to Advance First-in-Class Micro-Robotic Technology and Remove Barriers to Treat Rare and Debilitating Diseases – Bionaut Labs, the company that uses microscale robots to revolutionize the treatment of central nervous system (CNS) diseases and disorders, today announced $43.2M in a Series B round of financing led by Khosla Ventures, bringing the company’s total financing raised to date to $63.2 million. Also participating in the round are new investors Deep Insight, OurCrowd, PSPRS, Sixty Degree Capital, Dolby Family Ventures, GISEV Family Ventures, What if Ventures, Tintah Grace and Gaingels, along with all existing investors – Upfront Ventures, BOLD Capital Partners, Revolution VC, and Compound.
Foley Represents NEA as Lead Investor in $12M Series A Round for College Social Media App Fizz – Foley & Lardner LLP represented New Enterprise Associates (NEA) as the lead investor in the $12 million Series A funding round for Fizz, a social media app for college students. NEA was joined by additional investors Lightspeed, Rocketship, Owl Ventures, Smash Ventures, and New Horizon.
Fizz is a peer-moderated social media platform exclusively available for college campuses to create hyper-local digital communities where students can communicate about campus life. On the app, students can anonymously share messages, polls, and photos, and classmates can upvote or downvote what they see in their feed. Users can direct message each other, choosing whether to reveal their identity.
D2C Brand Rapidbox Secures $4.5 M In Series A Round – Rapidbox, a Bengaluru-based direct-to-consumer (D2C) brand, has announced a $4.5 million Series A round of funding led by SIG Venture Capital, Susquehanna International Group’s Asian venture capital arm. Tanglin Venture Partners, India Quotient, and Ananya Goenka are among the other investors in the round
QualSights nets $7.7m from series A funding round to propel growth – QualSights will now be able to introduce its technology to more brands and to further propel its growth in the American market after it raised $7.7 million in additional capital.
Its series A funding round was led by 4490 Ventures, an early-stage venture capital firm that is based in Madison, Wisconsin.
Strand Therapeutics Raises $45M in Series A1 Funding – Strand Therapeutics, a Boston, MA-based programmable mRNA company, raised $45M in Series A1 funding.
The round was led by FPV with participation from Eli Lilly and Company, Potentum Partners, and existing investors Playground Global, and a further unannounced syndicate.